What’s the current market cap for Generate Biomedicines stock?

Generate Biomedicines (GENB) has a market cap of $1.7bn as of June 12, 2026.

What is the P/E ratio for Generate Biomedicines stock?

The price to earnings (P/E) ratio for Generate Biomedicines (GENB) stock is 0 as of June 12, 2026.

Does Generate Biomedicines stock pay dividends?

No, Generate Biomedicines (GENB) stock does not pay dividends to its shareholders as of June 12, 2026.

When is the next Generate Biomedicines dividend payment date?

Generate Biomedicines (GENB) stock does not pay dividends to its shareholders.

What is the beta indicator for Generate Biomedicines?

Generate Biomedicines (GENB) does not currently have a Beta indicator.

Buy Generate Biomedicines stock | $GENB Share Price

13:30

15:10

16:45

18:25

20:00

About Generate Biomedicines

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Ticker

$GENB

Sector

Health

Primary listing

NASDAQ

Employees

312

Headquarters

Somerville, United States

Website

generatebiomedicines.com

GENB Metrics

BasicAdvanced

$1.7bn

-$4.57

What the Analysts think about GENB

Analyst ratings (Buy, Hold, Sell) for Generate Biomedicines stock.

Bulls say / Bears say

Generate Biomedicines reported $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which management expects will fund operations into the first half of 2028. (PRNewswire)

Generate’s GB-5267 MUC16 armored CAR-T program, developed in collaboration with Roswell Park Comprehensive Cancer Center, is expected to dose the first patient in the second half of 2026 in a Phase 1 trial for solid tumors, initially targeting ovarian cancer. (PRNewswire)

Generate’s lead candidate GB-0895 initiated first patient dosing in a Phase 3 severe asthma trial on January 26, 2026, with full enrollment expected by the first half of 2028. (Reuters)

Generate Biomedicines’ research and development expenses rose to $57.8 million in Q1 2026 from $46.8 million in Q1 2025, driving a net loss of $61.7 million versus $44.3 million a year earlier. (PRNewswire)

Generate’s stock opened at $15 per share on its Nasdaq debut, below its $16 IPO price, reflecting weaker market reception. (Reuters)

Generate remains pre-commercial, with Q1 2026 collaboration revenue of $7.2 million versus a net loss of $61.7 million, underscoring its reliance on external funding. (PRNewswire)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

GENB Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

GENB Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GENB

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Generate’s lead candidate GB-0895 initiated first patient dosing in a Phase 3 severe asthma trial on January 26, 2026, with full enrollment expected by the first half of 2028. (Reuters)

Generate’s stock opened at $15 per share on its Nasdaq debut, below its $16 IPO price, reflecting weaker market reception. (Reuters)

Generate remains pre-commercial, with Q1 2026 collaboration revenue of $7.2 million versus a net loss of $61.7 million, underscoring its reliance on external funding. (PRNewswire)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

About Generate Biomedicines

Ticker

Employees

GENB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about GENB

Analyst Ratings

Bulls say / Bears say

GENB Financial Performance

Income Statement

GENB Earnings Performance

Earnings per share (EPS)

Buy $GENB

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Generate Biomedicines/$GENB

About Generate Biomedicines

Ticker

Employees

GENB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about GENB

Analyst Ratings

Bulls say / Bears say

GENB Financial Performance

Income Statement

GENB Earnings Performance

Earnings per share (EPS)

Buy $GENB

Upcoming events

No upcoming events

What’s the current market cap for Generate Biomedicines stock?

What is the P/E ratio for Generate Biomedicines stock?

Does Generate Biomedicines stock pay dividends?

When is the next Generate Biomedicines dividend payment date?

What is the beta indicator for Generate Biomedicines?

Bulls say / Bears say